Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2870_Библиотеки_им_академика_М_И_Перельмана.pdf
200 New Medical Technology in Patient Care: A Physician’s Guide
or more so, than current animal models. Before OOCs can be used,
detailed and standardized protocols and reproducible results in an interlaboratory setting are required51 to develop a consensus.
52
As of this writing, organs-on-a-chip (OOC) technology has yet to be
formally approved by the FDA as a standalone tool for drug testing or
diagnostic purposes. However, the FDA has shown interest in its
potential.
The FDA has collaborated to evaluate the effectiveness of OOC systems. For instance, the FDA has collaborated with Emulate, Inc., a company specializing in OOC technology, to use their “Human Emulation
System,” which includes organs-on-chips, to study how human organs
respond to medicines, chemicals, and diseases.53 These collaborations aim
to understand better the potential of OOC technology in improving and
accelerating drug development and regulatory evaluations.
Conclusion
OOC technology, integrating microfabrication and tissue engineering,
offers microfluidic devices that emulate human organ functions. This
chapter highlighted its potential for more physiologically relevant drug
testing and disease modeling using human and patient-specific cells.
However, challenges such as long-term cell viability, complex organ interactions, and regulatory acceptance remain.
OOC technology is poised to transform drug development by enhancing drug screening accuracy, reducing animal testing, and aiding in personalized medicine. As technology advances, it could become a crucial
tool in regulatory science, improving new therapies’ safety and efficacy
evaluation.
OOC technology represents a significant advancement in medical
research and pharmaceutical development. Its ability to closely mimic
human physiology promises to streamline drug development, offer more
precise disease models, and facilitate personalized therapeutic approaches.
Overcoming current challenges will be critical to its integration into mainstream research and clinical practice, potentially marking a new era in
healthcare innovation.
Organ-on-a-Chip: Revolutionizing Medical Research 201
References
1. Herper M. The Cost of Creating a New Drug Now $5 Billion, Pushing
Big Pharma to Change. Forbes; 2013 Aug 11. http://www.forbes.com/sites/
matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-newdrugs-is-shaping-the-future-of-medicine/.
2. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg
SR, et al. How to improve R&D productivity: the pharmaceutical industry’s
grand challenge. Nat Rev Drug Discov. 2010;9(3):203–214.
3. Scott CW, Peters MF, Dragan YP. Human induced pluripotent stem cells
and their use in drug discovery for toxicity testing. Toxicol Lett.
2013;219(1):49–58.
4. Van Norman GA. Limitations of animal studies for predicting toxicity in
clinical trials: is it time to rethink our current approach? JACC Basic Transl
Sci. 2019;4(7):845–854.
5. Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze
of opportunities and challenges. Cell. 2015;163(1):39–53.
6. Tian C, Qin T, Liu W, Wang J. Recent advances in microfluidic technologies for organ-on-a-chip. TrAC Trends Anal Chem. 2019;117:146–156.
doi:10.1016/j.trac.2019.06.005.
7. Bhatia S, Ingber D. Microfluidic organs-on-chips. Nat Biotechnol.
2014;32:760–772. doi:10.1038/nbt.2989.
8. Ramadan Q, Zourob M. Organ-on-a-chip engineering: toward bridging the
gap between lab and industry. Biomicrofluidics. 2020 Jul 14;14(4):041501.
doi:10.1063/5.0011583. PMID: 32699563; PMCID: PMC7367691.
9. Zhang B, Korolj A, Lai BF, Radisic M. Advances in organ-on-a-chip engineering. Nat Rev Mater. 2018;3(8):257–278.
10. Cheriyedath S. What Is Microfluidics? News-Medical.net. 2024. https://
www.news-medical.net/life-sciences/What-is-Microfluidics.aspx. Accessed
2024 Jan 14.
11. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber
DE. Reconstituting organ-level lung functions on a chip. Science. 2010 Jun
25;328(5986):1662–1668. doi:10.1126/science.1188302. PMID: 20576885;
PMCID: PMC8335790.
12. Mathur A, Loskill P, Shao K, Huebsch N, Hong SG, Marcus SG, et al.
Human iPSC-based cardiac microphysiological system for drug screening
applications. Sci Rep. 2015;9:5:8883. doi:10.1038/srep08883.
202 New Medical Technology in Patient Care: A Physician’s Guide
13. Bovard D, Sandoz A, Luettich K, Frentzel S, Iskandar A, Marescotti D, et al.
A lung/liver-on-a-chip platform for acute and chronic toxicity studies. Lab
Chip. 2018;18(24):3814–3829. doi:10.1039/C8LC01029C.
14. Kim HJ, Li H, Collins JJ, Ingber DE. Contributions of microbiome and
mechanical deformation to intestinal bacterial overgrowth and inflammation
in a human gut-on-a-chip. Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):
E7–15. doi:10.1073/pnas.1522193112. Epub 2015 Dec 14. PMID: 26668389;
PMCID: PMC4711860.
15. Lee-Montiel FT, Laemmle A, Charwat V, Dumon L, Lee CS, Huebsch N,
et al. Integrated isogenic human induced pluripotent stem cell-based liver
and heart microphysiological systems predict unsafe drug-drug interaction.
Front Pharmacol. 2021 May 7;12:667010. doi:10.3389/fphar.2021.667010.
PMID: 34025426; PMCID: PMC8138446.
16. Mariano A, Conficconi C, Lemme M, Occhetta P, Gaudiello E, Votta E, et al.
Beating heart on a chip: a novel microfluidic platform to generate functional
3D cardiac microtissues. Lab Chip. 2016;16(3):599–610. doi:10.1039/
c5lc01356a.
17. Zhu J. Application of organ-on-chip in drug discovery. J Biosci Med.
2020;08(03). doi:10.4236/jbm.2020.83011.
18. Low LA, Tagle DA. Tissue chips — innovative tools for drug development
and disease modeling. Lab Chip. 2017 Sep 12;17(18):3026–3036.
doi:10.1039/c7lc00462a. PMID: 28795174; PMCID: PMC5621042.
19. Huh DD. A human breathing lung-on-a-chip. Ann Am Thorac Soc. 2015
Mar;12(Suppl 1):S42–S44. doi:10.1513/AnnalsATS.201410-442MG. PMID:
25830834; PMCID: PMC5467107.
20. Skardal A, Murphy SV, Devarasetty M, Mead I, Kang W, Seol YJ, et al.
Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform. Sci Rep. 2017;7(1):8837. doi:10.1038/s41598-017-08879-x.
21. Deng S, Li C, Cao J, Cui Z, Du J, Fu Z, Yang H, Chen P. Organ-on-a-chip
meets artificial intelligence in drug evaluation. Theranostics. 2023 Aug
15;13(13):4526–4558. doi:10.7150/thno.87266. PMID: 37649608; PMCID:
PMC10465229.
22. van der Meer AD, van den Berg A. Organs-on-chips: breaking the in vitro
impasse. Integr Biol (Camb). 2012;4(5):461–470. doi:10.1039/c2ib00176d.
23. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov. 2015 Apr;14(4):248–260. doi:10.1038/
nrd4539. Epub 2015 Mar 20. PMID: 25792263; PMCID: PMC4826389.
Organ-on-a-Chip: Revolutionizing Medical Research 203
24. Imparato G, Urciuolo F, Netti PA. Organ on chip technology to model
cancer growth and metastasis. Bioengineering (Basel). 2022 Jan 11;
9(1):28. doi:10.3390/bioengineering9010028. PMID: 35049737; PMCID:
PMC8772984.
25. Akhtar A, Andleeb A, Sher Waris T, Bazzar M, Moradi AR, Awan NR, et al.,
Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics. J Control Release. 2020;330:1152–1167.
doi:10.1016/j.jconrel.2020.11.021.
26. Milne CP. CNS Drugs Take 20% Longer to Develop and to Approve vs. Non-
CNS Drugs. Boston: Tufts Center for the Study of Drug Development. 2018.
https://www.globenewswire.com/news-release/2018/09/11/1569156/0/en/
CNS-Drugs-Take-20-Longer-to-Develop-and-38-Longer-to-Approve-vsNon-CNS-Drugs-According-to-the-Tufts-Center-for-the-Study-of-DrugDevelopment.html.
27. Spitz S, Ko E, Ertl P, Kamm RD. How organ-on-a-chip technology can assist
in studying the role of the glymphatic system in neurodegenerative diseases.
Int J Mol Sci. 2023;24(3):2171. doi:10.3390/ijms24032171.
28. Ma C, Peng Y, Li H, Chen W. Organ-on-a-chip: a new paradigm for
drug development. Trends Pharmacol Sci. 2021 Feb;42(2):119–133.
doi:10.1016/j.tips.2020.11.009. Epub 2020 Dec 16. PMID: 33341248;
PMCID: PMC7990030.
29. Ashammakhi N, Elmusrati M. An array of gut-on-a-chips for drug development. BioRxiv. 2018;273847.
30. Perelson AS, Ribeiro RM. Introduction to modeling viral infections and
immunity. Immunol Rev. 2018;285(1):5–8.
31. Hartung T. Toxicity testing in the 21st century. Nature. 2009;460:208–212.
32. Shahabipour F, Satta S, Mahmoodi M, Sun A, de Barros NR, Li S,
et al. Engineering organ-on-a-chip systems to model viral infections.
Biofabrication. 2023 Feb 6;15(2). doi:10.1088/1758-5090/ac6538. PMID:
35390777; PMCID: PMC9883621.
33. Xian C, Zhang J, Zhao S, Li XG. Gut-on-a-chip for disease models. J Tissue
Eng. 2023 Jan 18;14. doi:10.1177/20417314221149882. PMID: 36699635;
PMCID: PMC9869227.
34. Beaurivage C, Kanapeckaite A, Loomans C, Erdmann KS, Stallen J, Janssen
RAJ. Development of a human primary gut-on-a-chip to model inflammatory processes. Sci Rep. 2020;10(1):21475. doi:10.1038/s41598-02078359-2.
204 New Medical Technology in Patient Care: A Physician’s Guide
35. Thacker VV, Sharma K, Dhar N, Mancini GF, Sordet-Dessimoz J, McKinney
JD. Rapid endotheliitis and vascular damage characterize SARS-CoV-2
infection in a human lung-on-chip model. EMBO Rep. 2021;22(6):e52744.
36. Maulana TI, Kromidas E, Wallstabe L, Cipriano M, Alb M, Zaupa C, et al.
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. Adv Drug Deliv Rev. 2021;173:281–305. doi:10.1016/j.addr.2021.03.015.
https://www.sciencedirect.com/science/article/pii/S0169409X21000934.
37. Tibbitt MW, Anseth KS. Hydrogels as extracellular matrix mimics for 3D
cell culture. Biotechnol Bioeng. 2009 Jul 1;103(4):655–663. doi:10.1002/
bit.22361. PMID: 19472329; PMCID: PMC2997742.
38. Mastrangeli M, Millet S, ORCHID partners T, van den Eijnden-van Raaij J.
Organ-on-chip in development: towards a roadmap for organs-on-chip.
ALTEX. 2019;36(4):650–668. doi:10.14573/altex.1908271.
39. Ribas J, Sadeghi H, Manbachi A, Leijten J, Brinegar K, Zhang YS, et al.
Cardiovascular organ-on-a-chip platforms for drug discovery and development. Appl Vitro Toxicol. 2016 Jun 1;2(2):82–96. doi:10.1089/aivt.2016.0002.
PMID: 28971113; PMCID: PMC5044977.
40. Annabi N, Selimović Š, Acevedo Cox JP, Ribas J, Bakooshli A, Heintze D,
et al. Hydrogel-coated microfluidic channels for cardiomyocyte culture. Lab
Chip. 2013;13:3569–3577.
41. Duffy DC, McDonald JC, Schueller OJ, Whitesides GM. Rapid prototyping
of microfluidic systems in poly(dimethylsiloxane). Anal Chem.
1998;70(23):4974–4984.
42. Halldorsson S, Lucumi E, Gómez-Sjöberg R, Fleming RMT. Advantages and
challenges of microfluidic cell culture in polydimethylsiloxane devices.
Biosens Bioelectron. 2015;63:218–231.
43. Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat. Rev. Drug Discov. 2017;16(2):115–130.
44. van den Berg A, Mummery CL, Passier R, van der Meer AD. Personalised
organs-on-chips: functional testing for precision medicine. Lab Chip.
2019;19(2):198–205.
45. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: Past,
present, and future. Stem Cell Res Ther. 2019 Feb 26;10(1):68. doi:10.1186/
s13287-019-1165-5. PMID: 30808416; PMCID: PMC6390367.
46. Sung JH, Esch MB, Prot JM, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab
Chip. 2013;13(7):1201–1212. doi:10.1039/c3lc41017j.
Organ-on-a-Chip: Revolutionizing Medical Research 205
47. Maschmeyer I, Lorenz AK, Schimek K, Hasenberg T, Ramme AP, Hübner J,
et al. A four-organ-chip for interconnected long-term co-culture of human
intestine, liver, skin and kidney equivalents. Lab Chip. 2015;15(12):2688–
2699. doi:10.1039/C5LC00392J.
48. Wagner I, Materne EM, Brincker S, Süssbier U, Frädrich C, Busek M, et al.
A dynamic multi-organ-chip for long-term cultivation and substance testing
proven by 3D human liver and skin tissue co-culture. Lab Chip.
2013;13(18):3538–3547. doi:10.1039/c3lc50234a.
49. Mastrangeli M, Millet S, Mummery C, Loskill P, Braeken D, Eberle W, et al.
Building blocks for a European organ-on-chip roadmap. ALTEX.
2019;36(3):481–492. doi:10.14573/altex.1905221.
50. Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, et al.
Biology-inspired microphysiological systems to advance patient benefit and
animal welfare in drug development. ALTEX. 2020;37(3):365–394.
doi:10.14573/altex.2001241. Epub 2020 Feb 28. PMID: 32113184; PMCID:
PMC7863570.
51. Schneider MR, Oelgeschlaeger M, Burgdorf T, van Meer P, Theunissen P,
Kienhuis AS, et al. Applicability of organ-on-chip systems in toxicology and
pharmacology. Crit Rev Toxico. 2021;51(6):540–554. doi:10.1080/10408444.
2021.1953439.
52. Teixeira SG, Houeto P, Gattacceca F, Petitcollot N, Debruyne D, Guerbet M,
et al. National reflection on organs-on-chip for drug development:
new regulatory challenges. Toxicol Lett. 2032;388:1–12. doi:10.1016/j.
toxlet.2023.09.011. https://www.sciencedirect.com/science/article/pii/
S0378427423010548.
53. Unlock Human-Relevant Insights with Organ-Chips. Emulate. https://emulatebio.com/?utm_source=google&utm_medium=cpc&utm_
campaign=Unbranded_General&utm_term=organ_on_a_chip&utm_
term=organ%20on%20a%20chip&utm_source=adwords&utm_medium=
ppc&utm_campaign=Unbranded+General&hsa_cam=18716528387&hsa_
grp=144253413793&hsa_mt=e&hsa_src=g&hsa_ad=630861078857&hsa_
acc=8851317517&hsa_net=adwords&hsa_kw=organ%20on%20a%20
chip&hsa_tgt=kwd-329009267684&hsa_ver=3&gad_source=1&gclid=
CjwKCAiAzJOtBhALEiwAtwj8trmiSm_ns1JTrwS6TWhpXIoCrv0N0700k5vyqNoAr3prwPXGPlSdFhoCNKwQAvD_BwE. Accessed
2024 Jan 15.
This page intentionally left blankThis page intentionally left blankThis page intentionally left blankThis page intentionally left blank
Chapter 7
3D Organ Printing: Transforming
Transplantation and Tissue Repair
Introduction
Brief Overview of 3D Organ Printing
Three-dimensional (3D) organ printing, a remarkable fusion of biology,
technology, and medicine, stands at the forefront of one of the most exciting advancements in healthcare. This innovative process involves creating
3D, functional biological structures — such as tissues and organs — layer
by layer from bioinks, biomaterials containing living cells. The technology leverages principles from traditional 3D printing, adapted to handle
the complexities of human biology.
At its core, 3D organ printing utilizes specialized printers that deposit
layers of cells and biocompatible materials in precise configurations.
These layers, guided by digital models, gradually build up to form structures that closely mimic the natural composition of human tissues and
organs. The process involves a meticulous orchestration of cell types,
growth factors, and scaffolding materials to ensure the viability and functionality of the printed organs.
The Significance of this Technology in Modern Medicine
The implications of 3D organ printing in modern medicine are profound.
This technology addresses one of the most pressing challenges in healthcare:
207
208 New Medical Technology in Patient Care: A Physician’s Guide
the shortage of organ donors for transplantation. 3D organ printing could
drastically reduce transplant waiting lists and the associated complications
of immune rejection by providing a source of personalized organs.
Moreover, the applications for 3D organ printing transcend transplan-
tation. It opens new avenues in pharmaceutical research and drug testing,
allowing for more accurate and ethical testing methods by reducing reliance on animal models. Researchers can use printed tissues to study disease mechanisms, test drug efficacy, and explore new treatments in a
controlled and patient-specific manner.
In tissue repair and regenerative medicine, 3D organ printing offers
solutions for reconstructive surgeries, particularly in cases of severe injuries or congenital defects. The ability to print tissues that precisely match
a patient’s anatomy and cellular composition can lead to more effective
and personalized treatments.
3D organ printing is a technological marvel and a beacon of hope in
medicine. It promises to revolutionize transplantation, drug development,
and tissue repair, creating a new era where personalized and accessible
healthcare solutions are a reality.
Understanding 3D Printing Technology
Basic Principles of 3D Printing
3D printing, or additive manufacturing, creates 3D objects from a digital
file. It involves adding a material layer by layer to build a final product. This
contrasts with traditional subtractive manufacturing methods, where the
material is removed from a solid block to achieve the desired shape. The
basic steps in 3D printing include designing a 3D model in a computeraided design (CAD) program, slicing the model into thin horizontal layers,
and then sequentially printing these layers to form the complete object.
Evolution from Manufacturing to Bioprinting
Initially developed for industrial applications, 3D printing has evolved to
encompass bioprinting, a specialized form of 3D printing that uses living cells
and biomaterials to create tissue-like structures. This evolution was driven by
3D Organ Printing: Transforming Transplantation and Tissue Repair 209
Figure 1. Bioprinting process for skin repair.
the need for more complex and biologically relevant models in medical
research and the demand for personalized medical solutions. Bioprinting
leverages the foundational principles of 3D printing but introduces biological
components, making it a more complex and delicate process. See Figure 1.
For example, researchers at the Wake Forest Institute for Regenerative
Medicine have pioneered bioprinting, demonstrating the potential to print
skin cells onto burn wounds.
1
Fundamental Components: Bioinks, Printers, and Scaffolds
The orchestration of bioinks, printers, and scaffolds forms the cornerstone
of 3D bioprinting, a transformative technology.